3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Completed
2
Sponsor Class
OTHER
5
NIH
4
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
CNS
1
Conditions
Leukemia, Myeloid, Acute
5
Glioblastoma
4
Breast Neoplasms
4
Melanoma
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Glioma
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Advanced Ovarian Cancer
1
Advanced Cancer
1
Interventions
pembrolizumab
133
Gemcitabine
101
Paclitaxel
100
Carboplatin
84
Nivolumab
66
Docetaxel
62
Bevacizumab
62
Cisplatin
57
Pemetrexed
50
Fluorouracil
49
Cyclophosphamide
41
Cetuximab
41
trametinib
38
venetoclax
37
Leucovorin
37
Irinotecan
37
Sorafenib
35
Capecitabine
35
Ipilimumab
33
Dexamethasone
32
atezolizumab
31
Erlotinib Hydrochloride
28
130-nm albumin-bound paclitaxel
28
Drug Therapy
27
Epoetin Alfa
26
Doxorubicin
25
Oxaliplatin
24
Albumin-Bound Paclitaxel
24
Prednisone
23
Rituximab
22
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasms
×
sargramostim
×
Clear all
NCT01784913
2024-12-16
UV1/hTERT2012P
Ultimovacs ASA
Phase 1/2
Completed
22 enrolled
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled